Kjell E J Håkansson1,2, Eveline A C Goossens1,2, Stella Trompet3,4, Eva van Ingen1,2, Margreet R de Vries1,2, Reginald V C T van der Kwast1,2, Rasmus S Ripa5, Jens Kastrup5, Philipp J Hohensinner6, Christoph Kaun6, Johann Wojta6, Stefan Böhringer7, Saskia Le Cessie7,8, J Wouter Jukema3, Paul H A Quax1,2, A Yaël Nossent1,2,9. 1. Department of Surgery, K6-R, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands. 2. Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands. 3. Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands. 4. Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands. 5. Department of Cardiology, Rigshospitalet University of Copenhagen, Copenhagen, Denmark. 6. Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. 7. Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands. 8. Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands. 9. Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria.
Abstract
AIMS: We have shown that 14q32 microRNAs are highly involved in vascular remodelling and cardiovascular disease. However, the 14q32 locus also encodes 41 'orphan' small nucleolar RNAs (snoRNAs). We aimed to gather evidence for an independent role for 14q32 snoRNAs in human cardiovascular disease. METHODS AND RESULTS: We performed a lookup of the 14q32 region within the dataset of a genome wide association scan in 5244 participants of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Single nucleotide polymorphisms (SNPs) in the snoRNA-cluster were significantly associated with heart failure. These snoRNA-cluster SNPs were not linked to SNPs in the microRNA-cluster or in MEG3, indicating that snoRNAs modify the risk of cardiovascular disease independently. We looked at expression of 14q32 snoRNAs throughout the human cardio-vasculature. Expression profiles of the 14q32 snoRNAs appeared highly vessel specific. When we compared expression levels of 14q32 snoRNAs in human vena saphena magna (VSM) with those in failed VSM-coronary bypasses, we found that 14q32 snoRNAs were up-regulated. SNORD113.2, which showed a 17-fold up-regulation in failed bypasses, was also up-regulated two-fold in plasma samples drawn from patients with ST-elevation myocardial infarction directly after hospitalization compared with 30 days after start of treatment. However, fitting with the genomic associations, 14q32 snoRNA expression was highest in failing human hearts. In vitro studies show that the 14q32 snoRNAs bind predominantly to methyl-transferase Fibrillarin, indicating that they act through canonical mechanisms, but on non-canonical RNA targets. The canonical C/D-box snoRNA seed sequences were highly conserved between humans and mice. CONCLUSION: 14q32 snoRNAs appear to play an independent role in cardiovascular pathology. 14q32 snoRNAs are specifically regulated throughout the human vasculature and their expression is up-regulated during cardiovascular disease. Our data demonstrate that snoRNAs merit increased effort and attention in future basic and clinical cardiovascular research. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: We have shown that 14q32 microRNAs are highly involved in vascular remodelling and cardiovascular disease. However, the 14q32 locus also encodes 41 'orphan' small nucleolar RNAs (snoRNAs). We aimed to gather evidence for an independent role for 14q32 snoRNAs in humancardiovascular disease. METHODS AND RESULTS: We performed a lookup of the 14q32 region within the dataset of a genome wide association scan in 5244 participants of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Single nucleotide polymorphisms (SNPs) in the snoRNA-cluster were significantly associated with heart failure. These snoRNA-cluster SNPs were not linked to SNPs in the microRNA-cluster or in MEG3, indicating that snoRNAs modify the risk of cardiovascular disease independently. We looked at expression of 14q32 snoRNAs throughout the human cardio-vasculature. Expression profiles of the 14q32 snoRNAs appeared highly vessel specific. When we compared expression levels of 14q32 snoRNAs in human vena saphena magna (VSM) with those in failed VSM-coronary bypasses, we found that 14q32 snoRNAs were up-regulated. SNORD113.2, which showed a 17-fold up-regulation in failed bypasses, was also up-regulated two-fold in plasma samples drawn from patients with ST-elevation myocardial infarction directly after hospitalization compared with 30 days after start of treatment. However, fitting with the genomic associations, 14q32 snoRNA expression was highest in failing human hearts. In vitro studies show that the 14q32 snoRNAs bind predominantly to methyl-transferase Fibrillarin, indicating that they act through canonical mechanisms, but on non-canonical RNA targets. The canonical C/D-box snoRNA seed sequences were highly conserved between humans and mice. CONCLUSION: 14q32 snoRNAs appear to play an independent role in cardiovascular pathology. 14q32 snoRNAs are specifically regulated throughout the human vasculature and their expression is up-regulated during cardiovascular disease. Our data demonstrate that snoRNAs merit increased effort and attention in future basic and clinical cardiovascular research. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Victoria James; Zubair A Nizamudeen; Daniel Lea; Tania Dottorini; Terri L Holmes; Benjamin B Johnson; Kenton P Arkill; Chris Denning; James G W Smith Journal: Stem Cells Dev Date: 2021-12-15 Impact factor: 3.272
Authors: Eva van Ingen; Daphne A L van den Homberg; M Leontien van der Bent; Hailiang Mei; Nikolina Papac-Milicevic; Veerle Kremer; Reinier A Boon; Paul H A Quax; Johann Wojta; A Yaël Nossent Journal: Hum Mol Genet Date: 2022-03-31 Impact factor: 6.150
Authors: Christian A Tallo; Laura H Duncan; Akihiko H Yamamoto; Joshua D Slaydon; Gunjan H Arya; Lavanya Turlapati; Trudy F C Mackay; Mary A Carbone Journal: G3 (Bethesda) Date: 2021-01-18 Impact factor: 3.154
Authors: Eva van Ingen; Pleun A M Engbers; Tamar Woudenberg; M Leontien van der Bent; Hailiang Mei; Johann Wojta; Paul H A Quax; A Yaël Nossent Journal: Mol Ther Nucleic Acids Date: 2022-09-17 Impact factor: 10.183
Authors: Reginald V C T van der Kwast; Laura Parma; M Leontien van der Bent; Eva van Ingen; Fabiana Baganha; Hendrika A B Peters; Eveline A C Goossens; Karin H Simons; Meindert Palmen; Margreet R de Vries; Paul H A Quax; A Yaël Nossent Journal: Mol Ther Nucleic Acids Date: 2020-07-21 Impact factor: 8.886
Authors: Anne Yaël Nossent; Neda Ektefaie; Johann Wojta; Beate Eichelberger; Christoph Kopp; Simon Panzer; Thomas Gremmel Journal: Int J Mol Sci Date: 2019-11-27 Impact factor: 5.923